ABT-737

Catalog No.S1002

ABT-737 Chemical Structure

Molecular Weight(MW): 813.43

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 384 In stock
USD 120 In stock
USD 200 In stock
USD 570 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 90 Publications

16 Customer Reviews

  • Cardiomyocytes transduced with or without Ad-Mst1 were treated with ABT-737 (0, 0.1, 1, 10 uM) for 12 hours. Representative immunoblots with antibodies to p62/SQSTM1, LC3 and GAPDH are shown.

    Nat Med 2013 19(11), 1478-88. ABT-737 purchased from Selleck.

    BCL-XL mediates human neutrophil survival. PMNs were preincubated with the BH3 mimetic ABT-737 (1–10 μM), then cultured in normoxia (gray bars) with or without GM-CSF (500 U/ml) or hypoxia (white bars)or 20 hours, and apoptosis was assessed by morphology (n = 4).

     

     

    J Clin Invest 2011 121, 1053-1063. ABT-737 purchased from Selleck.

  • Release of mitochondrial cytochrome c and loss of mitochondrial membrane potential after exposure to ABT-737 (100nM) for 2 hours were assessed by immunohistochemistry and staining with TMRE (red, top panels) and anti-CD41/FITC (green, top panels). Bar represents 5 um. Note that control cells display spreading on glass slides, whereas ABT-737-treated cells do not.

    Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.

    Platelets were incubated in HBS with or without ABT-737 (100nM) for 2 hours before analysis by immunohistochemistry and confocal microscopy. Actin was stained using phalloidin/Alexa-488 (green), and tubulin was stained using anti-tubulin/phycoerythrin (red). Bar represents 5 uM.

    Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.

  • (B) The sensitivity (LD50) of CLL cells, assessed by annexin V staining after 48 h of treatment with ABT‐737, ABT‐263 or ABT‐199, was plotted against the pBcl‐2/Bcl‐2, Mcl‐1/Bcl‐2 and (pBcl‐2 + Mcl‐1)/Bcl‐2 ratios. Relative protein quantification was carried out with kodak carestream molecular imaging software and normalized to β‐actin. Spearman's correlation (r) and P values are shown. Data shown are representative of five independent experiments.

    Br J Pharmacol, 2016, 173(3):471-83. ABT-737 purchased from Selleck.

    Analysis of SW480 and SW620 cell sensitivity to the BH3-mimetic ABT-737. (a, b) Percentage of apoptosis in adherent or suspended SW480 (a) or SW620 (b) cells cultured in the presence (ABT-737) or absence (ctrl) of ABT-737 (1 uM).

    Cell death dis 2013 4, e801. ABT-737 purchased from Selleck.

  • Bcl-XL/Bcl-2 inhibitor ABT-737 aggravates the proapoptotic effects of IL-1IFN-. INS-1E cells were transfected with single or smart Pool PUMA siRNAs and exposed to ABT-737 for 24 h. At this time point, cell death was measured by HO/PI, n  3. *, p  0.05; **, p  0.01.
     

     

     

    J Biol Chem 2010 285, 19919-19920. ABT-737 purchased from Selleck.

    Effect of ABT-737 on the cell viability of CCRF-CEM cells by treatments of AY4 (10 μg/ml), TRAIL (0.5 μg/ml), SAHA (1 μM),VPA (1 mM), or ABT-737 (10 μM) alone or in combination for 24 h prior to MTT assay.

     

     

    Apoptosis 2010 15, 1256-1269. ABT-737 purchased from Selleck.

  • Upper panel ABT-737 inhibits TFK-1 and EGI-1 cell growth.Cells were exposed to ABT-737 at a concentration ranging from 1 to 50 lM. Following 72 h of incubation, growth inhibition was analyzed by crystal violet assay. Dose–effect plot of ABT-737 treatment is presented.

     

     

    Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.

    Lower panel detection of PARP-1, cleaved caspase-9 and caspase-3, BCL-2 and MCL-1 in TFK-1 and EGI-1 cells after 72 h of ABT-737 treatment (1, 3, 10, 25,50 μM). Cell lysates were analyzed on Western blotting.

     

     

    Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.

  • 3 μM ABT737 inhibited growth and viability of TF-1 cells and potentiated proapoptotic effects of 1 μM BIO after 72 hours treatment. TF-1 cells treated with both drugs exhibited more apoptotic cells compared to those treated with each single drug. ABT737 abrogated the protection from BIO-induced apoptosis provided by MS5 coculture.

     

     

    Exp Hematol 2010 38, 908-921. ABT-737 purchased from Selleck.

    GSIXII synergized with ABT-737 to trigger apoptosis in breast cancer cells . Breast cancer cell lines were incubate d for 48 hours with 10μM GSIXII or DMSO (Ct) in combination or not with ABT-737, 1 μM. Then apoptosis was evaluated with Apo2.7 or Annexin-V staining and flow-cytometry analysis. Represented data are the means of positive cells ± SEM, from three independent experiments.(A) Suboptimal concentrations of GSIXII (5 μM) and 1 μM ABT-737 were used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with mock-treated condition. (B) The 20 μM SAHM1 was used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with the mock-treated condition.

    Biochem Biophys Res Commun 2013 408, 344-9. ABT-737 purchased from Selleck.

  • Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2012 408, 344-9. ABT-737 purchased from Selleck.

    The combined use of ABT-737 and sorafenib changes the apoptotic effect. MC-3 cells were treated with the indicated compounds for 48 h. (A) Nuclear condensation and fragmentation were evaluated in DAPI-stained cells as described in the Materials and Methods (X400). (B) Live (green) and dead (red) cells were qualified using the Live/dead assay kit as described in the Materials and Methods (X200). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

    Arch Oral Biol, 2017, 73:1-6. ABT-737 purchased from Selleck.

  • MEF wt and MEF Mcl-1 ko mice activating active caspase-3 using 1um ABT for 24h

     

     

    Dr. Arnim Weber of Medizinische Mikrobiologie und Hygiene Universitatsklinikum Freiburg. ABT-737 purchased from Selleck.

    MDB-MA-231 cells were exposed to 30 um cisplatin in the absence or in thepresence of 100nm ABT-737.The cell were stained with Hoechst 33342,MitoTracker Red and Yo-pro-1.

     

     

    Dr. Zhang of Tianjin Medical University. ABT-737 purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.
Features First-generation inhibitor of anti-apoptotic Bcl-2 proteins.
Targets
Bcl-2 [1]
(Cell-free assay)
Bcl-xL [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
Bcl-B [1]
(Cell-free assay)
30.3 nM(EC50) 78.7 nM(EC50) 197.8 nM(EC50) 1.82 μM(EC50)
In vitro

ABT-737 shows low activity to Bcl-B and no effects to Mcl-1 and BFL-1. ABT-737 is sensitive to HL60, KG1 and NB4 cells with IC50 of 50 nM, 80 nM and 80 nM, respectively. ABT-737 induces apoptosis in HL60 cells, which due to decreased Bcl-2/Bax heterodimerization and has no effect on cell cycle distribution. ABT-737 also induces cytochrome c release from purified mitochondria and promotes conformational changes in Bax that are associated with apoptosis. [1] Resistant cells (Hela and MCF-7) can be sensitized to ABT-737 by approaches that down-regulate, destabilize, or inactivate Mcl-1. ABT-737 also causes Bax/BAK-dependent cytochrome c release only when Mcl-1 has been neutralized. [2] ABT-737 displaces Bim from Bcl2's BH3-binding pocket, allowing Bim to activate Bax, induce mitochondrial permeabilization, and rapidly commit the primary chronic lymphocytic leukemia (CLL) cells to death. [3] Knockdown of Mcl-1 with siRNA sensitizes two resistant SCLC cell lines H196 and DMS114 to ABT-737 by enhancing the induction of apoptosis. Likewise, up-regulation of Noxa sensitizes H196 cells to ABT-737. ABT-737 inhibits proliferation and induces apoptosis in many SCLC cell lines including NCI-H889, NCI-H1963, NCI-H1417, NCI-H146 and etc. Bcl-2 and Noxa may contribute mechanistically to the cellular response to ABT-737 in NCI-H146 cells. [4] A recent study shows that ABT-737 significantly induces apoptosis in HTLV-1 infected T-cell lines as well as in fresh ATLL cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OCI-Ly1  NXXqT3czS2WubDDWbYFjcWyrdImgRZN{[Xl? NIDycFczPTBibl5CpC=> MlPRO|IhcA>? NE\6NphFVVOR MoTHZ4F2e2WmIEm3KUBtd3O|IH;mJJZq[WKrbHn0fUBqdiClZXzsd{B1emGwc3\lZ5Rm\CC5aYToJGJEVDZic3nSUmE> Mn;INlY3PTd{OEi=
KG1a MV\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NFX4U4MxNTFyIN88US=> NHK3NVYzPCCq MYXEUXNQ MVvJR|UxRTdwNkig{txONCCmZXPy[YF{\XNiY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> Ml3MNlY2PTJ5MUK=
Kasumi-1 MXHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1flOlAuOTBizszN MYSyOEBp NHT5fodFVVOR NF3uV3NKSzVyPUSuPFch|ryPLDDk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M4nKdVI3PTV{N{Gy
KG1a NI\hd2dCeG:ydH;zbZMhSXO|YYm= MlnnNE0yOCEQvF2= NUjDUm1iOjRiaB?= NITKNWtFVVOR MUXpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NID6NIUzPjV3MkexNi=>
Kasumi-1 MUDBdI9xfG:|aYOgRZN{[Xl? NUPHU|JNOC1zMDFOwG0> NELkZ5UzPCCq MmTNSG1UVw>? NHTMWItqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NFzWOIszPjV3MkexNi=>
MC-3  Mk\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXIOU8yOC9{MDFOwG0> MkmzNlQhcA>? MmGySG1UVw>? NYLPc5dKcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MYmyOlQ1PzZzNR?=
HN22  MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HnUFIvPS95LkWvNlIvPSEQvF2= M4TsPFI1KGh? NHG2V5JFVVOR MWHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M{LUTVI3PDR5NkG1
MC-3  NYnrbFdXSXCxcITvd4l{KEG|c3H5 M1fTPVUwOTBxMkCg{txO MWqyOEBp NF3BXnJFVVOR MlXjbY5lfWOnczDjZZNx[XOnLX3l[IlifGWmIHHwc5B1d3Orcx?= M13BVVI3PDR5NkG1
HN22  MUnBdI9xfG:|aYOgRZN{[Xl? NYXWNFBKOi53L{euOU8zOi53IN88US=> NV61V3ZPOjRiaB?= NInpW|VFVVOR MkXmbY5lfWOnczDjZZNx[XOnLX3l[IlifGWmIHHwc5B1d3Orcx?= NWn1OllFOjZ2NEe2NVU>
MOLT-4 NF\mfZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXuWIpGOTBvNUCwNEBvVQ>? M4LrN|czKGh? NVz5ZZpMTE2VTx?= M1zacWlEPTB;MD6xPVgh|ryP MUeyOlM6OjN|Mh?=
RS4;11 MoHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rEU|ExNTVyMECgcm0> NIW3eXM4OiCq NVHBVVVnTE2VTx?= M{PWc2lEPTB;MD6wNFIh|ryP NX\4bZNOOjZ|OUKzN|I>
JURKAT NVHMZ2dHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vqNlExNTVyMECgcm0> NYrxVFA3PzJiaB?= MVPEUXNQ MW\JR|UxRTZ4IN88US=> NITmOpczPjN7MkOzNi=>
CEM R MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXGSI5OOTBvNUCwNEBvVQ>? NVj6[4c{PzJiaB?= MWfEUXNQ MUHJR|UxRTVwNDFOwG0> MnPpNlY{QTJ|M{K=
CEM S MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Pic|ExNTVyMECgcm0> M4W4ZlczKGh? NGD6bWRFVVOR MULJR|UxRTF{LkGg{txO NHXwblIzPjN7MkOzNi=>
MOLT-4 NHu5UJdCeG:ydH;zbZMhSXO|YYm= MVuxNE0yODByIH7N NHzId3gzPCCq NIjwRnRFVVOR NUL5RpFo[2G3c3XzJJRp\SClbHXheoFo\SCxZjDCZ4wuOiCjbnSgeIhmKGSxd37y[Yd2dGG2aX;uJI9nKEKlbD34UEBidmRiTXPsMVE> NXPxTYxTOjZ|OUKzN|I>
CEM S MWPBdI9xfG:|aYOgRZN{[Xl? NEW0OJYyOC1zMECwJI5O M3PJNFI1KGh? NWHtTplMTE2VTx?= MlvJZ4F2e2W|IITo[UBkdGWjdnHn[UBw\iCEY3ytNkBidmRidHjlJIRwf26{ZXf1cIF1cW:wIH;mJGJkdC26TDDhcoQhVWOuLUG= NWW0XZJvOjZ|OUKzN|I>
JURKAT M3f1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVWxNFAuOTByMDDuUS=> NFz2VWk1QCCq M3TlXGROW09? M{HmO2lEPTB;OUW1xtE6NjNibl2= MmnnNlYyPzJ{Nkm=
LOUCY MnTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\6ZlExOC1zMECwJI5O M323PFQ5KGh? NYTYbYNZTE2VTx?= MlXjTWM2OD1|Mj64xtEyOC57IH7N NUHZdGpwOjZzN{KyOlk>
WM-115 NEnwUIdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MWGxNFDDqG6P M3LhVVczKGh? MYHlcohidmOnczDjeZJkfW2rbj3pcoR2[2WmIHHueIkue3W{dnn2ZYzDqA>? NIjGdVczPjFzNke3Oi=>
B16 MnvkR4VtdCCYaXHibYxqfHliQYPzZZk> M1\3[lExOMLibl2= NHTGR244OiCq NH;EeIhmdmijbnPld{BkfXKldX3pck1qdmS3Y3XkJIFvfGlvc4Xyeol3[W{EoB?= MmHJNlYyOTZ5N{[=
HL-60  M371U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLRRmJvPzJiaB?= NI\ofoxKSzVywrC9JFExNjdibl2= NYjXZ4E4OjZyNEW2NFk>
MOLM-13  MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPlO3M4OiCq NYfNfnd7UUN3MNMgQUAzPy57IH7N M13jW|I3ODR3NkC5
OCI-AML3 MlTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGq0fnk4OiCq MlTtTWM2OMLiPTCxPVUxKG6P M{TSVlI3ODR3NkC5
BCWM.1 Ml7ZRZBweHSxc3nzJGF{e2G7 NX;SNHhlOC1zLk[g{txO NULHVVdoOjRiaB?= NULjUnpocW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NFrWSJYzPTh7M{K5NC=>
MWCL-1 MXrBdI9xfG:|aYOgRZN{[Xl? M{DzO|AuOS54IN88US=> NFfPOnYzPCCq NIjIRllqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MX2yOVg6OzJ7MB?=
MM.1s MV\BdI9xfG:|aYOgRZN{[Xl? NImwOI8xNTFwNjFOwG0> MWKyOEBp NG\VbHdqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NED0VmgzPTh7M{K5NC=>
HCT116 NYfIe4t7TnWwY4Tpc44hSXO|YYm= NWPY[3d4Oy9zMDFOwG0> MmDUNVLDqGkEoB?= NGnJfodFVVOR MlnHbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJGxEO0JvSVmgZ49vfmW{c3nvckBidmRiU2HTWG0yKGSnZ4Lh[IF1cW:w MlXrNlU4OTVyMki=
HCT116 BAX BAK1 DKO M{TDS2Z2dmO2aX;uJGF{e2G7 NGXwVYc{NzFyIN88US=> MWWxNuKhcMLi MX3EUXNQ MnrVbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJGxEO0JvSVmgZ49vfmW{c3nvckBidmRiU2HTWG0yKGSnZ4Lh[IF1cW:w NETHOlczPTdzNUCyPC=>
HCT116 NH7jbmtHfW6ldHnvckBCe3OjeR?= NGW2bY8yOCEQvF2= NHzOb5QyOsLiaNMg MlrySG1UVw>? M1P1bYlv[3KnYYPld{BITlBvTFOzRkBxfW6ldHG= MVmyOVcyPTB{OB?=
HCT116 BAX BAK1 DKO NX;LTpo{TnWwY4Tpc44hSXO|YYm= Mn;MNVAh|ryP NFXze2UyOsLiaNMg NYfzNYFlTE2VTx?= NHXwcY1qdmO{ZXHz[ZMhT0[SLVzDN2IheHWwY4Th MoDqNlU4OTVyMki=
HCT116 M3XRU2F2fG:yaHHnfUBCe3OjeR?= MkXpNVAh|ryP NWHlOmFROTMEoHlCpC=> M2nzXGROW09? MUnpcoR2[2W|IHGgZ49ueGyndHWgZZV1d3CqYXfpZ{Bz\XOyb37z[S=> NYTySHliOjV5MUWwNlg>
HCT116 BAX BAK1 DKO MlXTRZV1d3CqYXf5JGF{e2G7 MkexNVAh|ryP NIXaT40yOsLiaNMg NVrnPVV7TE2VTx?= NXzWPG97cW6mdXPld{BiKGOxbYDs[ZRmKGG3dH;wbIFocWNicnXzdI9ve2V? NWPvT|ZNOjV5MUWwNlg>
U937 MXjBdI9xfG:|aYOgRZN{[Xl? NYTUNnZEOC5zMkWtNkDPxE1? NWjqd5BLOjRiaB?= NVjLWFZG\W6qYX7j[ZMhTEiDL2itNVEucW6mdXPl[EBieG:ydH;zbZM> M3;xbVI2PzF2MEK0
U937  NYnrO4VGSXCxcITvd4l{KEG|c3H5 NXnaeGg2OC53IN88US=> NWLKdYpoOjRiaB?= NHW0cVdmdmijbnPld{BkdGWjdnHn[UBw\iCSQWLQJIFv\CClYYPwZZNmNTNiYYOge4VtdCCjczDOc5hiKGyndnXs MVmyOVcyPDB{NB?=
HL-60 AAA-Bcl-2 MYnBdI9xfG:|aYOgRZN{[Xl? MUGwMVUh|ryP MUK0PEBp NVSw[4g{UUN3ME2wMlg4KM7:bf-8kIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MUKyOVcyOTR4MB?=
HL-60 EEE-Bcl-2 M2H0bWFxd3C2b4Ppd{BCe3OjeR?= M2LyfVAuPSEQvF2= NGjVNo81QCCq MUTJR|UxRTVizszt89yNKGmwZIXj[ZMh[2WubDDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M13RbFI2PzFzNE[w
U87 MV7GeY5kfGmxbjDBd5NigQ>? MWq1NEDPxE1? M1SyNlI1KGh? MUPy[YR2[2W|IITo[UBuWk6DIHX4dJJme3Orb36gcIV3\Wy|IH;mJG1OWC1{LDDNUXAuOTRiYX7kJGJkdC1{ NHPoeoIzPTZ4N{[2Ny=>
K562 NGK1VnBE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NF;UWJgyNTFyIN88US=> NETLdYw1QCCq M3\m[WROW09? NIDKZppKSzVyPUK2Mlch|ryP M{G2OlI2PTl4NU[x
K562/Mcl -1-IRESBim NXHpUFZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fDdmlEPTB;OT6zJO69VQ>? NXPMZ4hWOjV3M{W5NFA>
K562/Bcl- 2-IRESBim MlTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mki3TWM2OD1yLkO1JO69VQ>? NWK0eIJkOjV3M{W5NFA>
Jurkat Moq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWr0VJZVUUN3ME2wMlY3KM7:TR?= M1vxdFI2PTN3OUCw
JurkatΔBak MnqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\Zc41CUUN3ME61NEDPxE1? MYGyOVU{PTlyMB?=
HL60/VCR MljXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfNbohKSzVyPkGwNEDPxE1? M3jKNFI2PTN3OUCw
Kasumi-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fodGlEPTB;MD6wNUDPxE1? M2jPV|I2PTN3OUCw
Kasumi-1/ABT NWT2dYZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;qPGlEPTB;MD61NUDPxE1? NHTMVZUzPTV|NUmwNC=>
THP-1 NFjvfFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTFwMkeg{txO M4PFblI2PTN3OUCw
U937 MnvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTVwMkmg{txO MVOyOVU{PTlyMB?=
C1498 Mn[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETaUndKSzVyPU[uNVMh|ryP MXWyOVU{PTlyMB?=
RPMI 8226 MlXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfObZVKSzVyPUCuNlUh|ryP M3HnRVI2PTN3OUCw
MM.1S NWm5XY5lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\RNWlEPTB;MD60NEDPxE1? NWO3NGtHOjV3M{W5NFA>
NCI-H929 NVLnOmlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTF3LkKxJO69VQ>? MWCyOVU{PTlyMB?=
U266 MnvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYezS3pKUUN3ME2wMlY5KM7:TR?= M2XRWFI2PTN3OUCw
MCF-7 NWPLU5lES2WubDDWbYFjcWyrdImgRZN{[Xl? Ml;BOUDPxE1? M3vGSFQ5KGh? M1fWZWROW09? M4jMVYVvcGGwY3XzJJRp\SC|ZX7zbZRqfmm2eTD0c{BweiC{YXTpZZRqd25? NYK0VnBkOjV2MEmxNlQ>
MCF-7 NH7uPVdCeG:ydH;zbZMhSXO|YYm= M2frbVUh|ryP NULre5ltPC9{ND:0PEBp NHnFV3lFVVOR Mki2bY5kemWjc3XzJJRp\SClbHXheoVlKFCDUmC= MlnNNlU1ODlzMkS=
MCF-7 NXzzdYVCTnWwY4Tpc44hSXO|YYm= MmrNOUDPxE1? M3mxUlI1KGh? MoX4SG1UVw>? NHrGPJNmdmijbnPld{B1cGWuZY\lcEBw\iCPY3ytNUBmgHC{ZYPzbY9vyqB? M1TyVFI2PDB7MUK0
MDA-MB 231  MkXsSpVv[3Srb36gRZN{[Xl? M2ntTFUh|ryP NH;wTpAzPCCq MXTEUXNQ M1u4coVvcGGwY3XzJJRp\WyndnXsJI9nKE2lbD2xJIV5eHKnc4Ppc47DqA>? NWC5NWpPOjV2MEmxNlQ>
ZR-75-1  NVXnTXlWTnWwY4Tpc44hSXO|YYm= NG\oOJQ2KM7:TR?= M3;uWVI1KGh? M1fvSmROW09? M{XpNIVvcGGwY3XzJJRp\WyndnXsJI9nKE2lbD2xJIV5eHKnc4Ppc47DqA>? M1\iSVI2PDB7MUK0
A549 MWPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1vFTFAuOjBizszN NEi3dG04OiCq M330dWROW09? M{HmcIRm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkBkd22kaX7l[EB4cXSqIHHzdIlzcW5? MVWyOVM5QDd4Mh?=
H1299 MUPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MmXVNE0zOCEQvF2= Mlm1O|IhcA>? NIjUWXJFVVOR NFnSeG1l\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw NGTKXJQzPTN6OEe2Ni=>
HO-8910 MYrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MkjZNE0zOCEQvF2= MV[3NkBp NIX6[HlFVVOR NV7aPVVs\GWlcnXhd4V{KHSqZTDj[YxtKHO3co\peoFtKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKGOxbXLpcoVlKHerdHigZZNxcXKrbh?= M3nNcFI2Ozh6N{[y
HT-29 NGHJTYFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MmKwNE0zOCEQvF2= NUPIOGdVPzJiaB?= NF\udZpFVVOR M2jGboRm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkBkd22kaX7l[EB4cXSqIHHzdIlzcW5? NXXac3pQOjV|OEi3OlI>
HCT-116 NIf6UphE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M3rVWVAuOjBizszN MXe3NkBp Mn7mSG1UVw>? MkfO[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJINwdWKrbnXkJJdqfGhiYYPwbZJqdg>? NGnmO3AzPTN6OEe2Ni=>
A549 MofYRZBweHSxc3nzJGF{e2G7 NFPURWEzOCEQvF2= M4DuWVQ5KGh? MmrZSG1UVw>? M2Dy[4lv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEBie3Crcnnu Mlq0NlU{QDh5NkK=
H1299 M{fDUGFxd3C2b4Ppd{BCe3OjeR?= M{fIVFIxKM7:TR?= NF7n[IY1QCCq MnHuSG1UVw>? NVn1VYpDcW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKGG|cHnybY4> M3H5XlI2Ozh6N{[y
Sc-1 MknSR4VtdCCYaXHibYxqfHliQYPzZZk> NWjze3hbOC5yMECxMVEh|ryP NFrkUYE6PiCq MlTL[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NYTWWJlGOjV|N{O1NFg>
OcI-LY18 Mmf2R4VtdCCYaXHibYxqfHliQYPzZZk> NXjxSJp6OC5yMECxMVEh|ryP NF7mPIo6PiCq NGexS|dl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NVfDW|NyOjV|N{O1NFg>
RL  NEj0d|JE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NV7zXZJmOC5yMECxMVEh|ryP NYDyVWs2QTZiaB?= M3XrWYRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NFnkeJUzPTN5M{WwPC=>
RKO NVzjNXdYS2WubDDWbYFjcWyrdImgRZN{[Xl? MoLCNE0yOCEQvF2= MWOyOQKBkWkEoB?= MnTYSG1UVw>? NIPHWFRKSzVyPvMAjVI26oDLwsXN NX3oe|VvOjV|MESzPFM>
Caco-2 MX7D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NWDROYF5OC1zMDFOwG0> NHnkWI8zPOLCiXlCpC=> M2\WcmROW09? MnqwTWM2OD1zOT635qCKyrWP MWCyOVMxPDN6Mx?=
DLD1 NYTyVWRrS2WubDDWbYFjcWyrdImgRZN{[Xl? NEDDfGwxNTFyIN88US=> NIHEbZAzPOLCiXlCpC=> MX7EUXNQ M3zmNWlEPTB;MUiuO|jjiIoEtV2= M3zENVI2OzB2M{iz
LS411N MV\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> M{jvXFAuOTBizszN NWT3bXc6OjUkgJnoxsA> NWW2NXVyTE2VTx?= NXjLbphyUUN3ME2xNU41P+LCidM1US=> NFq1SWUzPTNyNEO4Ny=>
SW620 MVvD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MYWwMVExKM7:TR?= M2rN[|I16oDLaNMg NXKyTGJRTE2VTx?= M{LqTmlEPTB;MUKuNlTjiIoEtV2= NUfwcIxIOjV|MESzPFM>
HCT116 NF25fWNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NHn4cZcxNTFyIN88US=> MY[yOQKBkWkEoB?= NVraZnJVTE2VTx?= M3;O[GlEPTB;MkCuOFnjiIoEtV2= NEnmelkzPTNyNEO4Ny=>
HaCaT M2rw[2NmdGxiVnnhZoltcXS7IFHzd4F6 NVO0VHlwOC5zL{GvNVAh|ryP MnziNlQhcA>? M1fXTGROW09? MkS2[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NITlTFQzPTJzMEe5OS=>
A5-RT3 M1XFRmNmdGxiVnnhZoltcXS7IFHzd4F6 M3nGUlAvOS9zL{GwJO69VQ>? NFXPO28zPCCq M1PGUGROW09? NUjkc4k6\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MknxNlUzOTB5OUW=
HaCaT MmfYSpVv[3Srb36gRZN{[Xl? M2L2clEx6oDLzszN M1POT|I1NzR6IHi= NV3qeWNXTE2VTx?= MmO0bY5lfWOnczDNUXAh[W6mIFTORUBnemGpbXXueIF1cW:w MV:yOVIyODd7NR?=
A5-RT3 NV3nfIpGTnWwY4Tpc44hSXO|YYm= M1e4dlEx6oDLzszN NIXQcnUzPC92ODDo MkXNSG1UVw>? NXHOfo9scW6mdXPld{BOVVBiYX7kJGRPSSCocnHncYVvfGG2aX;u NULZSZR3OjV{MUC3PVU>
A5-RT3 NYmyVIVUTnWwY4Tpc44hSXO|YYm= NUm1bplJPSEQvF2= NXrCcI0{PiCq NVz2O3Y3TE2VTx?= MojFbY5lfWOnczD0bIUhemWuZXHz[UBw\iCvaYTvZ4hwdmS{aXHsJJBzd3SnaX7zJIFv\CC{ZXT1Z4V{KGOub37v[4VvcWNic4Xyeol3[WxiaX6gZUBk[XOyYYPlMYlv\GWyZX7k[Y51KG2jbn7ldi=> NEHuZVEzPTJzMEe5OS=>
U266 MV3GeY5kfGmxbjDBd5NigQ>? M{DTOVUxOC95NUCgcm0> M2roTlI1NzR6IHi= MYrEUXNQ NGnMdFZld3ewcnXneYxifGW|IFLpcUwheHKrbnPpdIFtdHlidHjlJGVNKGm|b3\vdo0> NV71TmpPOjV{MEi4PFg>
RPMI8226 M{XZeWZ2dmO2aX;uJGF{e2G7 MVu1NFAwPzVyIH7N MV2yOE81QCCq MUPEUXNQ M3GzeIRwf26{ZXf1cIF1\XNiQnntMEBxemmwY3nwZYxtgSC2aHWgSWwhcXOxZn;ycS=> MWKyOVIxQDh6OB?=
MM.1S M2Lre2Z2dmO2aX;uJGF{e2G7 NGH2ZYo2ODBxN{WwJI5O MlewNlQwPDhiaB?= MXrEUXNQ M2PDdoRwf26{ZXf1cIF1\XNiQnntMEBxemmwY3nwZYxtgSC2aHWgSWwhcXOxZn;ycS=> NWDoRlF2OjV{MEi4PFg>
Clone A NUDQ[WlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDwNE4z6oDVNkCg{txO NHvVS2U4OiCq NGfWcJlFVVOR NWnzUJo4UUN3ME23MlUh|ryP NX:zVIFIOjV{MEi4PFI>
CX-1 Mm\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\WOlQxNjMkgKO2NEDPxE1? MXi3NkBp NHXoTo1FVVOR M{TER2lEPTB;MT64JO69VQ>? M{HFflI2OjB6OEiy
LS174T MkHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTZXpRLOC5{4pETOlAh|ryP M13Xc|czKGh? NVPwNll[TE2VTx?= MYjJR|UxRTF6LkOg{txO MlTpNlUzODh6OEK=
HT29 NXvnXFB4SXCxcITvd4l{KEG|c3H5 MVKxM|UwOTBizszN MojKOFghcA>? NHPVV5Nk[XW|ZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> Mmj5NlUyQTJzOEi=
SW480 M4H2TmFxd3C2b4Ppd{BCe3OjeR?= M1ezblEwPS9zMDFOwG0> NGnme3M1QCCq MXPjZZV{\XNiY3XscEBl\WG2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M3TYRVI2OTl{MUi4
Colo205 MXrBdI9xfG:|aYOgRZN{[Xl? MV:xM|UwOTBizszN M4TNfVQ5KGh? NI\qbFZk[XW|ZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> Mlz3NlUyQTJzOEi=
Caco2 Ml7yRZBweHSxc3nzJGF{e2G7 MYOxM|UwOTBizszN NWPEOGsyPDhiaB?= NH3acGJk[XW|ZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> Ml3QNlUyQTJzOEi=
PCI-13 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVK3NkBp M13sfGROW09? MlTsS2k2OD1zNTFCtUAyNjhizszN MYeyOVE{QTN6Nx?=
PCI-15B MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPXPJlIPzJiaB?= Mn6wSG1UVw>? MmP2S2k2OD1zMTFCtUA1NjVizszN NX\uTVg2OjVzM{mzPFc>
UM-SCC22B MnmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jy[FczKGh? M4ryUGROW09? MlPyS2k2OD1zOTFCtUAzNjlizszN MkDNNlUyOzl|OEe=
UM-SCC47 MmTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;SWJQ4OiCq MkHKSG1UVw>? MmDVS2k2OD1zOTFCtUAyOi5|IN88US=> NWfOUlB1OjVzM{mzPFc>
93-VU-147T MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TqflczKGh? MkDnSG1UVw>? NH7hNXNIUTVyPUSuN{DDuSB|LkWg{txO MV6yOVE{QTN6Nx?=
UD-SCC2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLNO|IhcA>? M37LSWROW09? NILTZnVIUTVyPUK4JOKyKDJwOTFOwG0> Mk[5NlUyOzl|OEe=
UPCI:SCC90 MkL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmG3O|IhcA>? NWf2VppjTE2VTx?= NUfzfGhFT0l3ME22MlYhyrFiMT61JO69VQ>? M2jtdVI2OTN7M{i3
RPMI-8226  NVjMRmp6S2WubDDWbYFjcWyrdImgRZN{[Xl? MWSxNlUwOjVyL{WwNEBvVQ>? M1nhWFQ5cMLi NH75PVVFVVOR MorV[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NEL4e5IzPTByOEKwNi=>
OPM-2  MkT1R4VtdCCYaXHibYxqfHliQYPzZZk> MmLxNVI2NzJ3MD:1NFAhdk1? NGnmSlQ1QGkEoB?= MlXHSG1UVw>? M2PC[IRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NFjJTmozPTByOEKwNi=>
RPMI-8226  NHS0RpVCeG:ydH;zbZMhSXO|YYm= MXuxNlUwOjVyL{WwNEBvVQ>? MV:0PIjDqA>? NEnhdYZFVVOR MoizbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NW\ieXQ4OjVyMEiyNFI>
OPM-2  Mn;mRZBweHSxc3nzJGF{e2G7 NF[ydFMyOjVxMkWwM|UxOCCwTR?= NUPhdmp{PDiqwrC= MkL1SG1UVw>? MV7pcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NWS4SZZCOjVyMEiyNFI>
COG-LL-319 NHrTeWZHfW6ldHnvckBCe3OjeR?= MlLZNVAxKG6P MmTtNU8{NzZiaB?= MULEUXNQ MkflbY5lfWOnczDjZZNx[XOnLXTldIVv\GWwdDDNZ4wuOSClbHXheoFo\Q>? NHfMWYYzPDl3MUS3Ni=>
RS4;11 M33WfGZ2dmO2aX;uJGF{e2G7 M2rXOlExOCCwTR?= NHu5cXMyNzNxNjDo MmPDSG1UVw>? NIHVelBqdmS3Y3XzJINie3Cjc3Wt[IVx\W6mZX70JG1kdC1zIHPs[YF3[Wen MkXUNlQ6PTF2N{K=

... Click to View More Cell Line Experimental Data

In vivo In aggressive leukemia model, ABT-737 suppresses the leukemia burden by 53% at the 30 mg/kg, with significantly extended survival of mice. ABT-737 does not induce significantly abnormalities in blood cell counts or serum chemistries. [1] ABT-737 prolongs the survival of recipient mice transplanted with Bcl-2-transduced tumors. [2] ABT-737 shows great antitumor activity in an ATLL mouse model at a dose of 100 mg/kg. [5]

Protocol

Kinase Assay:

[1]

+ Expand

Fluorescence polarization assays:

Binding affinity of GST-Bcl-2 family proteins to the FITC-conjugated BH3 domain of Bim (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is determined. Briefly, 100 nM of GST-Bcl-2 family fusion proteins are incubated with serial dilutions of ABT-737 in PBS for 2 min. Then, 20 nM of FITC-Bim BH3 peptide (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is added. Fluorescence polarization is measured using an Analyst TM AD Assay Detection System after 10 min using the 96-well black plate. Then IC50 are determined.
Cell Research:

[4]

+ Expand
  • Cell lines: SCLC cell lines NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR, and DMS114
  • Concentrations: 0.001-10 μM
  • Incubation Time: 48 hours
  • Method:

    SCLC cells are treated for 48 hours in 96-well tissue culture plates in a total volume of 100 μL tissue culture medium supplemented with 10% human serum. Viable cells are determined using the MTS assay.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Scid mice injected with Luc-expressing FD/ΔRaf-1:ER cells
  • Formulation: 1 g/mL stock solution of ABT-737 in DMSO is added to a mixture of 30% propylene glycol, 5% Tween 80, 65% D5W (5% dextrose in water) (pH 4−5; final concentration of DMSO ≤ 1%)
  • Dosages: 20 and 30 mg/kg
  • Administration: For intraperitoneal (i.p.) every day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (122.93 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
30% Propylene glycol, 5% Tween 80, 65% D5W
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 813.43
Formula

C42H45ClN6O5S2

CAS No. 852808-04-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What’s the recommended method about reconstitution of the compound for in vivo animal study?

  • Answer:

    For oral administration, we suggest the vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W, at up to 30mg/ml; For injection, ABT-737 can be dissolved in 2% DMSO/50% PEG 300/5% Tween 80/ddH2O at 2.5 mg/ml.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy ABT-737 | ABT-737 supplier | purchase ABT-737 | ABT-737 cost | ABT-737 manufacturer | order ABT-737 | ABT-737 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID